Genetic Technologies (GTG.AX) Azione Prezzo
Genetic Technologies Prezzo
Il fatturato di Genetic Technologies si è contratto del 1,4% all'anno negli ultimi 18 anni, scendendo a 7,66 Mio. AUD. Per Genetic Technologies, il margine netto del -156,8% risulta in aumento rispetto al -61.830,2% di alcuni anni fa.
Genetic Technologies Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Genetic Technologies Azione e analisi azionaria
Domande frequenti sull'azione Genetic Technologies
The business model of Genetic Technologies Ltd revolves around genetic analysis and testing services. The company specializes in developing and commercializing genetic risk assessment tools for various diseases and conditions. Genetic Technologies uses advanced genetic screening and analysis techniques to assess an individual's predisposition or susceptibility to certain diseases, thereby aiding in personalized healthcare and preventive medicine. By leveraging its proprietary technologies and intellectual property, Genetic Technologies aims to provide valuable genetic insights and solutions to healthcare providers, insurance companies, and individuals worldwide.
Genetic Technologies Ltd is primarily active in the biotechnology and healthcare industries.
The main competitors of Genetic Technologies Ltd in the market include companies such as Myriad Genetics Inc., Quest Diagnostics Incorporated, and Illumina Inc. These companies operate within the genetic testing and diagnostics industry, offering similar products and services. However, Genetic Technologies Ltd distinguishes itself by leveraging its innovative technology and expertise to provide unique solutions in the field of genetic testing. As a leading player in this market, Genetic Technologies Ltd continuously strives to maintain its competitive edge through research and development, strategic partnerships, and expanding its product portfolio to cater to the growing demands and challenges of the industry.
Genetic Technologies Ltd is a renowned biotechnology company specializing in genetic testing and analysis. Established in 1989, the company has a rich history of over three decades in the field. Genetic Technologies has emerged as a leader in developing and commercializing innovative gene-based solutions for various industries, including healthcare, agriculture, and forensic sciences. With a strong focus on genetic research, the company has garnered international recognition for its expertise in DNA analysis, genotyping, and molecular diagnostics. Genetic Technologies Ltd continues to pioneer advancements in genetic science, empowering individuals and businesses with valuable genetic insights and solutions.
Genetic Technologies Ltd, a leading biotechnology company, has achieved numerous significant milestones throughout its journey. The company has successfully developed innovative genetic testing solutions, positioning itself as a pioneer in the field. Genetic Technologies Ltd has gained recognition for its breakthrough research and development, resulting in the development of commercially viable products. Additionally, the company has formed strategic partnerships, expanding its reach and enhancing its market presence. With its dedication to advancing genetic technologies, Genetic Technologies Ltd has secured valuable patents and intellectual property rights, further solidifying its position as a key player in the industry. Overall, Genetic Technologies Ltd has a proven track record of accomplishments, making it a compelling choice for investors seeking growth opportunities in the biotech sector.
Genetic Technologies Ltd is primarily present in Australia, where it is headquartered. The company operates in multiple regions within Australia, including Victoria and Queensland. As a global provider of molecular risk assessment tools, Genetic Technologies also has a presence in the United States. With an aim to improve healthcare through innovative genetic testing solutions, Genetic Technologies Ltd continues to expand its reach and strive for advancements in the field of genomics.
Genetic Technologies Ltd represents a commitment to genetic research and innovation in the field of personalized medicine. The company's core values include integrity, scientific excellence, and a strong focus on patient care. With a vision to enhance healthcare outcomes through genetic testing, Genetic Technologies aims to provide cutting-edge solutions to assist healthcare providers and empower individuals in making informed decisions about their health. By leveraging advanced technologies and partnerships, Genetic Technologies demonstrates a corporate philosophy centered on driving advancements in genomics and improving the quality of global healthcare.
Convertita al tasso di cambio attuale, l’azione Genetic Technologies quota 0,02 EUR (0,04 AUD).
L’azione Genetic Technologies (GTG.AX) è quotata su 3 borse, tra cui: ASX (GTG.AX), Frankfurt (DU8.F).
Genetic Technologies Ltd is an international company specializing in the development of genetic tests and diagnostic kits. It was founded in 1989 and is headquartered in Melbourne, Australia. The company has become a leading provider in personalized medicine and genetic analysis. They offer a wide range of genetic tests for various conditions such as cancer, cardiovascular diseases, osteoporosis, and neurological disorders. They also provide diagnostic kits that are easy to use and provide quick results, making the treatment process easier for patients. Additionally, they engage in research and development to expand their portfolio of medical solutions. The company holds patents in the field of genetic analysis and licenses its technologies to other organizations. Some of their products include BRCA tests for identifying genetic mutations associated with breast and ovarian cancer, BREVAGenplus for assessing an individual's risk of developing breast cancer, CardioID for determining a person's risk of cardiovascular diseases, and COVID-19 tests for diagnosing coronavirus infections. With their innovative solutions in personalized medicine and genetic analysis, Genetic Technologies Ltd continuously expands its existing business areas and actively seeks new opportunities.
Il attesa fatturato di Genetic Technologies ammonta a 28,60 Mio. AUD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto per Genetic Technologies non può essere attualmente calcolato.
Il P/E per Genetic Technologies non può essere attualmente calcolato.
Il rapporto prezzo/fatturato (P/S) di Genetic Technologies è attualmente 0,20. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Genetic Technologies.
Il Quality Score AlleAktien per Genetic Technologies è 2/10.
L'ISIN di Genetic Technologies è AU000000GTG7. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Genetic Technologies è 893882. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Genetic Technologies è GTG.AX. Con questo simbolo di borsa vengono negoziate le azioni Genetic Technologies in borsa.
Azione Genetic Technologies
Gruppo di pari di Genetic Technologies
Genetic Technologies Ticker
Genetic Technologies FIGI
Altre metriche e analisi di Genetic Technologies in Deep Dive.
La nostra analisi azionaria dell'azione Genetic Technologies include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Genetic Technologies. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: